UCSD Head and Neck Squamous Cell Carcinoma Trial: BCA101 Monotherapy and in Combination Therapy in Patients With EGFR‑driven Advanced Solid Tumors
BCA101 is a first‑in‑class bifunctional antibody targeting both EGFR and TGF‑β that may exert synergistic activity in patients with EGFR‑driven tumors.
This first‑in‑human Phase 1/1b, open‑label, multicenter study evaluates the safety, tolerability, pharmacokinetics and preliminary efficacy of BCA101, a novel bifunctional EGFR/TGF‑β fusion protein, alone and in combination with pembrolizumab, in patients with EGFR‑driven advanced solid tumors, including head and neck squamous cell carcinoma, squamous cell carcinoma of the anal canal, colorectal cancer, and others.
Identifying effective targeted therapies for EGFR‑driven tumors is critical for patients who have exhausted standard treatments; BCA101’s dual blockade of EGFR and TGF‑β pathways offers a potentially novel therapeutic option.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability